ILIAS Biologics Receives 'One More Step' Australian Phase 1 Clinical Report Of Anti-Inflammatory Exosome Treatment 'ILB-202' Before Global Technology
2024-06-11 · ILIAS Biologics Inc. · original iliasbio.com ↗
ILIAS Biologics Co., Ltd. (CEO Choi Chul-hee, hereinafter ILIAS) received the final result report (Clinical Study Report, CSR) of the phase 1 clinical trial of ILB-202, a company's leading pipeline exosome treatment completed in Australia in November last year. All 18 subjects completed the trial without dropout and no dose-limiting toxicity (DLT) including death or serious adverse events (SAEs) was observed at all doses. In addition, no injection-related reactions or cytokine storms were reported, confirming the high safety of "ILB-202". Please check out the link below for more information. News Link PREV LIST NEXT Ilias Company name ILIAS Biologics Inc. CEO Chulhee Choi Corporate registration number 161-86-00309 ADDRESS 40-20 Techno 6-ro, Yuseong-gu, Daejeon, 34014, Republic of Korea TEL 042-863-4450 FAX 042-863-4499 ⓒ 2021 ILIAS Biologics Inc. ALL RIGHTS RESERVED.
The release as fetched from its publisher. iliasbio.com ↗